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The patient characteristics and outcomes were studied in the 
318 patients who survived open label drug titration in the 
Cardiac Arrhythmia Suppression Trial (CAST) and who were 
not randomized to double-blind therapy and in 942 patients, 
who were randomized to double-blind placebo therapy. The 
patients randomized to placebo therapy had a lower total 
mortality or resuscitated cardiac arrest rate (4% vs. 8.5%). 
However, at baseline, nonrandomized patients were dissimilar 
from patients randomized to placebo in the following ways: older; 
lower left ventricular ejection fraction; greater use of digitalis, 
diuretic drugs and antihypertensive agents; lesser use of beta-
adrenoceptor blocking agents and more frequent prior cardiac 
problems, including runs of ventricular tachycardia and left 
bundle branch block. 
A matched comparison that took these inequities into account 
showed no significant differences in mortality or rate of resusci-
tation from cardiac arrest between nonrandomized patients and 
clinically equivalent patients randomized to placebo. Cox regres-
sion analysis indicated that two factors significantly increased the 
hazard ratio for arrhythmic death or resuscitated cardiac arrest in 
the nonrandomized patients: female gender (4.7, p < 0.05) and 
The mortality rate noted in the Cardiac Arrhythmia Suppres-
sion Trial (CAST) participants whose ventricular premature 
depolarizations were suppressed during open label drug 
titration and who were randomized to placebo therapy was 
noted (I) to be lower than that recently reported in compa-
rable study groups. However, the mortality rate for all 
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electrocardiographic events (ventricular tachycardia, proarrhyth-
mia, widened QRS complex, heart block, bradycardia) during 
open label titration (7.0, p < 0.005). However, some potentially 
important differences between men and women were not included 
in the Cox regression model. Of the nonrandomized patients, 
approximately 70% were not randomized because of lack of 
suppression of ventricular premature depolarizations or adverse 
events, or both, and the remaining 30% because of patient or 
private physician request with no indication of another reason. 
In conclusion, nonrandomized patients had more extensive 
coronary heart disease and experienced higher mortality and 
resuscitated cardiac arrest rates than did patients randomized to 
placebo. This finding at least partly explains the low mortality rate 
in the CAST patients randomized to placebo. Events such as 
proarrhythmia during drug titration portend a high risk of 
arrhythmic death. Many of the patients who most need antiar-
rhythmic benefit are unable to tolerate these drugs. In CAST, 
virtually all patients who could and would be treated with an 
antiarrhythmic drug were randomized. 
(J Am Coli CardioI1991;18:20-8) 
CAST patients who entered open label drug titration is 
comparable with that of recent studies (2) of similar post-
myocardial infarction patients. Some of the reasons for the 
apparent discrepancy in these observations are examined in 
the present analysis. 
One of the unique features of the CAST protocol (I) is the 
open label drug titration phase. This phase provides an 
opportunity to examine deaths and patient withdrawals for 
reasons such as proarrhythmia, lack of arrhythmia suppres-
sion, and other adverse events during open label titration 
before randomization to double-blind therapy. Mortality 
during open label titration and subsequent mortality in 
patients withdrawn before randomization are distinct from 
and not included in the analysis of those patients randomized 
to double-blind therapy. The present analysis examines the 
mortality rate in the patients who survived open label drug 
titration but who withdrew and were not randomized to 
double-blind therapy. 
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The purposes of this analysis were to: 1) tabulate the 
reasons why such patients were not randomized; 2) examine 
in detail the mortality rate in this group of nonrandomized 
patients for predictors of mortality among their baseline 
characteristics and events during open label titration; 3) 
compare baseline characteristics of these nonrandomized 
patients with those of patients randomized to placebo; and 4) 
compare the mortality rate in these nonrandomized patients 
with that in patients matched for baseline characteristics 
who were randomized to double-blind placebo therapy. 
Methods 
CAST protocol. A description of the CAST protocol has 
been previously published (1). Briefly, CAST is a double-
blind, randomized, placebo-controlled trial designed to test 
the hypothesis that suppression of ventricular premature 
depolarizations that cause mild or no symptoms will reduce 
the incidence of arrhythmic death in patients recovering 
from myocardial infarction. Patients who had at least 6 
ventricular premature depolarizations/h on a 24 h ambula-
tory electrocardiogram (ECG) recorded up to 2 years after a 
documented myocardial infarction were eligible. Patients 
whose index myocardial infarction occurred ~90 days be-
fore qualification were excluded when left ventricular ejec-
tion fraction was >0.55; those whose index infarction was 
>90 days old were excluded when left ventricular ejection 
fraction was >0.40. The protocol and consent form were 
reviewed and approved by the Institutional Review Board of 
each of the participating centers and each Institutional 
Review Board met United States Health and Human Sci-
ences guidelines. 
After qualification and after providing informed consent, 
patients entered the open label drug titration phase of the 
protocol, wherein they were equally likely to begin therapy 
with the drug sequence encainide-moricizine-flecainide or 
flecainide-moricizine-encainide when left ventricular ejec-
tion fraction was ~0.30 or encainide-moricizine or mori-
cizine-encainide when left ventricular ejection fraction was 
<0.30. Two different doses of each agent were used (1). 
Attempts to suppress ventricular premature depolarizations 
with antiarrhythmic drugs were continued until ~80% reduc-
tion in total ventricular premature depolarizations and ~90% 
reduction in runs of ventricular premature depolarizations 
were achieved without intolerable adverse effects. When 
such suppression was achieved, the patients were random-
ized in a double-blind fashion to the effective dose of 
antiarrhythmic drug or a matching placebo. In addition, 
patients who achieved some but not full suppression criteria 
with at least one drug and dose were randomized to placebo 
or the best drug and dose. 
Some patients died during this open label drug titration 
phase and their characteristics will be reported elsewhere. In 
addition, some patients survived the open label antiarrhyth-
mic drug titration phase but for various reasons were not 
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randomized to double-blind therapy. This last category of 
patients is the focus of the present report. 
Study patients. To ensure that the present analysis does 
not include any residual effects of drug titration, the study 
group comprises only those patients who survived for 10 
days after completion of open label drug titration. Deaths 
potentially attributable to drug titration were not included in 
the analysis. The period of 10 days was chosen on the basis 
of the half-lives of encainide, flecainide, moricizine and their 
metabolites and was considered to be sufficient time for 
these compounds to be washed out. Thus, deaths occurring 
within 10 days of completion of open label drug titration are 
reported with deaths occurring during titration. 
Patient follow-up. Follow-up procedures for patients ran-
domized to double-blind therapy have been previously de-
scribed (1). Follow-up evaluation of no nrandomi zed patients 
was accomplished according to a prospectively defined 
protocol. All patients who were not randomized into the 
double-blind phase were followed up by direct contact and, 
when that was not possible, by telephone contact every 6 
months with the patient or the patient's physician or family, 
alone or in combination. In the event of death, the principal 
investigator at the clinical center of the patient gathered all 
available data and classified the death according to CAST 
criteria (1). Thus, vital status as of April 19, 1989 is known 
for all 318 patients in this group and for all 942 patients 
randomized to placebo. 
Data analysis. All data reported in the present study are 
extracted from the CAST data base as of March 15, 1990. 
Comparisons of baseline characteristics are by the chi-
square or t statistic, as appropriate. Multivariable analysis 
for predictors of survival time utilized the Cox proportional 
hazards regression model (3). 
A cohort matched to the nonrandomized patients was 
obtained from the patients randomized to placebo. Impor-
tant variables identified at baseline comparison of the two 
groups were assigned numeric weightings according to their 
perceived importance. The variables used were gender, age, 
history of heart failure, history of previous myocardial 
infarction, use of a beta-adrenoceptor blocking agent at 
baseline study, widened QRS complex at baseline study, left 
ventricular ejection fraction and time from index myocardial 
infarction to randomization. The absolute difference of these 
weights was totaled for each potential pairing of a non-
randomized patient and a patient randomized to placebo. 
The algorithm of Gale and Shapley (4) was then used to 
obtain an "optimal" match (that is, one that approximately 
minimized the sum of the weighted differences from all 
possible matches). Comparison of these matched cohorts 
was then based on Kaplan-Meier estimation of survival rates 
and the log-rank statistic (5). 
Definitions 
The definitions of events are the same as those used for all 
analyses and reports of CAST data. 
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Arrhythmic death or resuscitated cardiac arrest. These 
events included witnessed instantaneous death in the ab-
sence of severe left ventricular failure or shock that in itself 
might have been expected to cause death; resuscitated 
ventricular fibrillation (or if no rhythm documentation is 
available, resuscitated cardiac arrest; that is, resuscitated 
ventricular tachycardia is not counted as an "arrhythmic 
death"); or unwitnessed death without other known noncar-
diac causes (1). 
Total mortality or resuscitated cardiac arrest. These 
events included all deaths, cardiac and noncardiac, and 
resuscitated cardiac arrest. 
Adverse clinical symptoms. These were symptoms that 
the CAST investigator attributed as definitely or possibly 
due to the drug and that were severe enough to preclude 
further use of the drug. 
Proarrhythmia. This was defined as a specified predeter-
mined increase in frequency of runs of ventricular premature 
depolarizations. The formula used to determine if their 
frequency was proarrhythmic was (In y) 2:3.118 + 0.646 
(In x), where x = ventricular premature depolarizations per 
hour at baseline and y = ventricular premature depolariza-
tions per hour during drug therapy (6). Proarrhythmia de-
fined by runs of ventricular premature depolarizations was 
2:50 runs124 h when there were <5 runs at baseline or a 
2: 10-fold increase in runs of ventricular premature depolar-
izations when there were 2:5 runs/24 h at baseline. 
New or worsened congestive heart failure. The presence 
of congestive heart failure was assessed by a CAST investiga-
tor. New congestive heart failure was defined when at least 
two different symptoms (shortness of breath, fatigue, orthop-
nea, paroxysmal nocturnal dyspnea) or signs Gugular venous 
distension> 10 em water, pulmonary rales, accentuated S3' 
edema) were present when no symptoms (using the same 
definition) had been noted at baseline study. Worsened con-
gestive heart failure was defined as an increase in one or 
more classes of the New York Heart Association classifi-
cation. 
Disqualifying ventricular tachycardia. Ventricular tachycar-
dia was defined as 2:3 successive complexes at 2:120 beats/ 
min; disqualifying ventricular tachycardia was defined as 
symptomatic (other than palpitation) unsustained ventricular 
tachycardia or asymptomatic or mildly symptomatic sustained 
ventricular tachycardia (2:15 complexes at 2:120 beats/min). 
Other ECG disqualifications. A variety of other ECG 
findings also served to disqualify a patient from enrollment in 
the double-blind portion of the study. These included pro-
longation of the QTc interval (1.4 times baseline or :::::0.6 s), 
heart rate <30 beats/min, pauses :::::3.5 s, Mobitz type II 
second degree atrioventricular (A V) block, advanced or 
third degree A V block and QRS duration 2:2 times base-
line or 2:0.2 s. Bradycardia or heart block disqualifications 
were removed if a permanent pacemaker had been im-
planted. 
Results 
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Mortality in nonrandomized patients and patients random· 
ized to placebo. A total of 318 nonrandomized patients 
survived for 2: 10 days after termination of open label drug 
titration. Of these 318 patients, 291 were alive or without 
resuscitated cardiac arrest on April 19, 1989, and the average 
exposure time was 300 days. Twenty-five patients had died 
and two had been resuscitated from a cardiac arrest; 8.5% 
were dead or resuscitated from a cardiac arrest. Among 
these 25 deaths, 8 (32%) were arrhythmic deaths, 12 (48%) 
were other cardiac deaths (9 due to heart failure, 3 to 
ischemia) and 2 (8%) were noncardiac deaths. There were 
three unclassified deaths. Among the patients who were 
randomized to double-blind placebo therapy, 942 survived 
for 2: 10 days after completion of open label drug titration 
and these patients were selected as the comparison group. 
Of these 942 patients, 904 were alive without death or 
resuscitated cardiac arrest on April 19, 1989 (average expo-
sure time 334 days). Thirty-four had died and four had been 
resuscitated from a cardiac arrest; 4% died or were resusci-
tated from cardiac arrest. Among the randomized patients, 
there were 18 arrhythmic deaths (53%), 9 other cardiac 
deaths (4 due to heart failure, 5 to ischemia) (27%) and 7 
noncardiac deaths (21%). The different proportions of ar-
rhythmic death in the two groups (32% vs. 53%) were not 
significantly different (p = 0.07). 
Comparison of baseline characteristics between nonran· 
domized patients and patients randomized to placebo. A total 
of 74 baseline variables were available for comparison. To 
provide an overview, a selection of these is presented in 
Table 1. On average, nonrandomized patients were 2 years 
older than patients randomized to placebo and more fre-
quently had prior cardiac problems, including heart failure, 
angina, myocardial infarction, cardiac revascularization and 
other types of cardiovascular surgery. A higher percent of 
nonrandomized patients had runs of ventricular tachycardia 
and left bundle branch block and their mean left ventricular 
ejection fraction was 3% units lower than that in patients 
randomized to placebo. Use of digitalis, diuretic drugs and 
antihypertensive agents was higher, whereas use of beta-
adrenoceptor blocking agents was lower in nonrandomized 
patients. 
Comparison of mortality during foUow.up study in nonran· 
domized patients and a matched cohort of patients randomized 
to placebo. The baseline variables of the nonrandomized 
patients and the matched cohort of patients randomized to 
placebo were compared and the matching process eliminated 
most of the baseline discrepancies noted in Table 1. Two 
exceptions were that fewer patients randomized to placebo 
were taking digitalis (24% vs. 34%) or calcium channel 
blockers (42% vs. 50%). Accordingly, these two groups 
appear to be comparable. Among the nonrandomized pa-
tients, 18 (6%) received individualized antiarrhythmic drug 
therapy prescribed by their private physicians during the 
follow-up period. The drugs used included amiodarone (n = 
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Table 1. Baseline Characteristics in Nonrandomized Patients and 
Patients Randomized to Placebo 
Patients 
Nonrandomized Randomized 
Patients to Placebo 
No. 318 942 
Age (yr) 63 ± 10 61 ± 10' 
Male gender 79 83 
History before MI 
CHF 23 12t 
Angina 52 44' 
Cardiac arrest 3 3 
VT 5 3 
Prior MI 46 37t 
PTCAICABG 22 17' 
Other cardiovascular surgery 2 1 '
Location of qualifying MI 
Q waves present 77 74 
Anterior 24 24 
Lateral 10 8 
Inferior 22 24 
Qualifying Holter ECG findings 
VPDIh 107 ± 202 126 ± 250 
VT runs 
None 71 79' 
I 16 11 
2-5 8 6 
~6 5 4 
LBBB 4 2' 
LVEF (%) 35 ± II 38 ± lOt 
Medication 
Beta-blocker 25 31' 
Calcium channel blocker 50 47 
Digitalis 34 21t 
Nitrate 50 45 
Diuretic drug 44 34t 
Antihypertensive agent 33 24t 
'p :5 0.05; tp :5 om. Unless otherwise stated, all values are in percent. 
CABG = coronary artery bypass graft surgery; CHF = congestive heart 
failure; LBBB = left bundle branch block; L VEF = left ventricular ejection 
fraction; MI = myocardial infarction; PTCA = percutaneous transluminal 
coronary angioplasty; VPD = ventricular premature depolarizations; VT = 
ventricular tachycardia. 
7), procainamide (n = 4), quinidine (n = 3), propafenone 
(n = 2), flecainide (n = 1) and mexiletine/sotalol (n = 1). 
Kaplan-Meier mortality curves for the two groups for the 
primary CAST end point of arrhythmic death or resuscitated 
cardiac arrest are presented in Figure 1. Similarly, survival 
curves for the secondary CAST end point of total mortality 
or resuscitated cardiac arrest are presented in Figure 2. 
There were no significant differences between groups by this 
analysis, but the small number of events meant that the 
power for a "no difference" conclusion was very low. 
Clinical correlates of mortality in nonrandomized patients. 
The factors associated with death or resuscitated cardiac 
arrest in nonrandomized patients were analyzed by Cox 
regression analysis (Table 2). A total of 18 variables were 
evaluated for association with arrhythmic death or resusci-
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Figure 1. Kaplan-Meier mortality curves comparing nonrandomized 
patients with a matched cohort of patients randomized to placebo 
for the primary Cardiac Arrhythmia Suppression Trial (CAST) end 
point of arrhythmic death or resuscitated cardiac arrest. Vertical axis 
is percent of patients with an event; horizontal axis is time in days, 
starting from 10 days after the patient left open label titration (see 
text). The nominal p value quoted is from the log-rank statistic. 
tated cardiac arrest and for association with total mortality 
or resuscitated cardiac arrest. The 18 variables were selected 
on the basis of known risk factors and differences at baseline 
evaluation, such as those outlined in Table 1. Those with a 
p value <0.2 by univariate analysis for either end point are 
shown in Table 2. With respect to the primary CAST end 
point (that is, arrhythmic death or resuscitated cardiac 
arrest), multivariate analysis indicated that two factors sig-
nificantly increased the hazard ratio for this end point in the 
nonrandomized patients, namely, ECG events during anti-
arrhythmic drug titration and female gender. There were 86 
Figure 2. Kaplan-Meier mortality curve comparing nonrandomized 
patients with a matched cohort of patients randomized to placebo 
for the secondary Cardiac Arrhythmia Suppression Trial (CAST) 
end point of total mortality or resuscitated cardiac arrest. Format as 
in Figure 1. 
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Table 2. Cox Regression Analysis. for Arrhythmic Death or Cardiac Arrest and for Total Mortality 
or Cardiac Arrest in Nonrandomized Patients 
Arrhythmic Death or Resuscitated Total Mortality or Resuscitated 
Cardiac Arrest Cardiac Arrest 
Univariate 
Multivariate 
Univariate 
Multivariate 
Relative Selection Hazard Relative Selection Hazard 
Risk Risk Ratio Risk Order Ratio 
Female gender 5.5* 2 4.7t 2.2t 3 2.Jt 
Prior history of heart 2.2 2.3' 
failure 
Baseline drug therapy 
Diuretic 2.9t 1.8 
Beta-blocker 2.0 4 3.5t 1.3 
EF <OJ 1.5 2.lt 2 2Jt 
Titration results 
Heart failure 3.4t 3 5.U 3.4' 3.5t 
ECG event 6.2' 7.0' 1.6 
Duration <4 wk 2.7 1.6 
'p 5 0.005; tp 5 0.05; tp 5 0.10. ECG event = electrocardiographic event (disqualifying ventricular tachycardia, 
proarrhythmia; ECG disqualification) during titration; EF = ejection fraction; Heart failure = new or worsened 
congestive heart failure. 
patients with ECG events during titration (some had more 
than one event)-79 with proarrhythmia, 22 with disqualify-
ing ventricular tachycardia and 22 with other ECG disqual-
ifications. New or worsened congestive heart failure during 
titration and treatment with a beta-adrenoceptor blocking 
agent at baseline study also tended to have a higher hazard 
ratio (p :::; 0.1). 
Differences in the baseline characteristics of nonrandom-
ized men and women were compared. The following differ-
ences (p :::; 0.05) were noted: women were older (67 vs. 62 
years); more frequently had non-Q wave myocardial infarc-
tion (37% vs. 21%), left bundle branch block (15% vs. 2%) 
and diabetes (31% vs. 18%); more frequently used diuretic 
drugs (59% vs. 40%) and nitrates (63% vs. 47%); less 
frequently were white (69% vs. 83%) and smokers (37% vs. 
43%) and less frequently had thrombolytic therapy (10% vs. 
27%). Among these factors, those not included in the Cox 
regression analysis were race, present smoking history and 
use of nitrates or thrombolytic therapy. 
Two significant factors emerged from Cox regression 
analysis based on the secondary end point of total mortality 
or resuscitated cardiac arrest-new or worsened congestive 
heart failure during open label titration and left ventricular 
ejection fraction <0.3. However, the multivariate hazard 
ratios were generally lower for the end point of total mor-
tality or cardiac arrest than for the end point of arrhythmic 
death or cardiac arrest. 
Reasons for withdrawal of nonrandomized patients. A 
small number (5%) of patients withdrew from the study 
before starting antiarrhythmic drug titration; most of these 
withdrew at their physician's or their own request without 
apparent adverse events (Table 3). 
The open label titration protocol involved as many as six 
drug/dose trials and lasted :::;90 days. The titration evalua-
tion forms were reviewed to characterize for each patient the 
major reason that he or she did not enter into the double-
blind phase of the study. Table 3 displays these reasons for 
withdrawal of the 318 nonrandomized patients. Among the 
302 patients who started the titration phase, the most com-
Table 3. Reasons for Withdrawal of Nonrandomized Patients 
No. % 
Never started titration 16 5 
Withdrew (patient or private physician request) 13 4 
Disqualifying ventricular tachycardia :j. Congestive heart failure 
Patient lost to follow-up >90 days I 
Disqualifying event during titration 38 12 
Started titration but withdrew (patient or private physician 137 43 
request) 
Without any adverse event recorded 72 23 
With adverse event recorded 65 20 
Did not complete titration within 90 days 34 11 
Without any adverse event recorded 22 7 
With adverse event recorded 12 4 
Completed titration but no VPD suppression 84 26 
Without any adverse event recorded 35 11 
With adverse event recorded 49 15 
Completed titration with complete or partial VPD 9 3 
suppression 
Withdrew (patient or private physician request) 7 2 
Disqualifying event (1 ventricular tachycardia, I syncope) 2 I 
Total 318 100 
*These three reasons for withdrawal = 1%. Adverse events = disquali-
fying event, proarrhythmia, adverse clinical symptoms; Disqualifying event = 
ventricular tachycardia, increased creatine kinase (;::2.5 mg/IOO ml), syncope, 
other ECG disqualification or new or worsened congestive heart failure 
unresponsive to discontinuation of Cardiac Arrhythmia Suppression Trial 
(CAST) drug or petmanent pacemaker; VPD = ventricular premature depo-
larization. 
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Table 4. Comparison of Arrhythmia Suppression Status Obtained 
in Nonrandomized Patients and Patients Randomized to Placebo 
During Dose Ranging With the First Drug Tested 
Arrhythmia Status 
VPD suppression 
Lack of VPD suppression 
Not assessed 
Total 
Nonrandomized 
Patients 
No. % 
5 2 
98 31 
215 68 
318 100 
VPD = ventricular premature depolarization. 
Patients 
Randomized 
to Placebo 
No. % 
715 76 
153 16 
74 8 
942 100 
mon reason for withdrawal was a disqualifying or adverse 
event during open label titration. This occurred alone or in 
combination with other reasons in 166 patients. The protocol 
did not require documentation of minor adverse clinical 
symptoms and absence of recording does not exclude 
mild side effects as the reason for patient withdrawal. 
In 38 patients, it was clear that a disqualifying event 
had occurred and another 65 were withdrawn at their 
physician's or their own request after an adverse event 
was recorded. Thus, withdrawals for adverse events in 
the absence of information on ventricular premature depo-
larization suppression status probably account for nearly 
33% of the 318 patients. Seventy-two patients (23%) started 
titration and were then withdrawn at their physician's or 
their own request without any record of an adverse event. 
For the reasons just indicated, however, it should not be 
assumed that all of these patients were free of adverse 
effects. 
Thirty-four (11 %) of the nonrandomized patients were not 
able to complete titration within the prescribed 90 days and 
12 of these had an adverse event recorded. Another 84 (26%) 
were not entered into the study because their ventricular 
premature depolarizations were not suppressed and titration 
had been completed. Furthermore, 35 of the latter 84 pa-
tients also had adverse events recorded. Thus, 226 (71%) of 
the 318 patients were withdrawn because of adverse events 
or lack of suppression within 90 days, or both. 
Only 9 (3%) of the 318 patients met ventricular premature 
depolarization suppression criteria for randomization to 
double-blind therapy but were not randomized. Two of 
these had a disqualifying event recorded to explain with-
drawal. Thus, the total number withdrawn without adverse 
effects or lack of suppression within 90 days, or both, was 
92 (29%). 
Comparison of results of open label titration on the first 
drug in nonrandomized patients and patients randomized to 
placebo. The data in Table 3 required subjective assessment 
after review of multiple data forms for each patient. A 
potentially more objective assessment is obtained by analy-
sis of the results of open label titration on the first drug. This 
allows comparison between the nonrandomized patients and 
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Table 5. Comparison of Outcomes From Drug Titration in 
Nonrandomized Patients and Patients Randomized to Placebo 
Whose Ventricular Premature Depolarization Suppression 
Status Was Not Assessed During Dose Ranging With the First 
Drug Tested 
Patients 
Nonrandomized Randomized 
Patient Continued Titration or 
Patients to Placebo 
Withdrew No. % No. % 
No event recorded 
Patient decision 39 18 0 0 
Private physician decision 5 2 1 
CAST investigator decision 14 7 7 10 
Subtotal 58 27 8 11 
Event recorded 
Adverse clinical symptoms 55 26 39 53 
Proarrhythmia 33 15 14 19 
Heart failure 26 12 5 7 
VT 13 6 0 0 
Other ECG disqualification 10 5 3 4 
Recurrent MI 3 0 0 
Miscellaneous 1 2 3 
Subtotal 141 66 63 85 
Missing data forms 16 7 3 4 
Total 215 100 74 100 
CAST = Cardiac Arrhythmia Suppression Trial; other abbreviations as in 
Tables 1 and 2. 
patients randomized to placebo. The "best" results (sup-
pression> lack of suppression> not assessed) with respect 
to ventricular premature depolarization suppression during 
dose ranging on the first drug tried during open label drug 
titration are presented in Table 4. Of the nonrandomized 
patients, 31% demonstrated only lack of ventricular prema-
ture depolarization suppression with the first drug, whereas 
the majority (76%) of the patients randomized to placebo 
demonstrated ventricular premature depolarization suppres-
sion with the first drug tried. The protocol did not require 
documentation of ventricular premature depolarization sup-
pression status when the patient was not going to continue 
that drug or dose for whatever reason (for example, occur-
rence of a disqualifying or adverse event or persistent 
palpitation). Accordingly, 68% of the nonrandomized pa-
tients compared with only 8% of the patients randomized to 
placebo did not have their ventricular premature depolariza-
tion suppression status assessed during treatment with the 
first drug. 
Table 5 displays other outcomes during dose ranging with 
the first drug for patients whose ventricular premature 
depolarization status was not assessed during administration 
of that drug. In the absence of a persistent disqualifying 
event, these patients would have been eligible to start 
treatment with the second drug if they had not withdrawn. 
The patients randomized to placebo who continued titration 
more commonly had adverse clinical symptoms (53% vs. 
26%) recorded while taking the first drug. Conversely, 
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the nonrandomized patients tested during administration 
of the first drug withdrew or started treatment with the 
second drug by their own choice (18% vs. 0%). The nonran-
domized patients more frequently had congestive heart 
failure or ventricular tachycardia (18% vs. 7%) recorded 
while taking the first drug. Other types of events did not 
preclude patients randomized to placebo from trying another 
drug that successfully suppressed the arrhythmia and did not 
appear to be any more prevalent in the nonrandomized 
patients. 
Discussion 
Mortality in nonrandomized patients and patients random-
ized to placebo. The total mortality or resuscitated cardiac 
arrest rate was significantly greater among nonrandomized 
patients in comparison with patients randomized to placebo. 
Clearly, this observation partly explains the low mortality 
rate in patients randomized to placebo (1). However, the 
baseline variables show that the two groups of patients are 
not comparable and these differences need to be considered 
in light of the different mortality experience. The types of 
death tended to differ in the two groups (p = 0.07). Death 
due to heart failure or ischemia was most frequent in 
nonrandomized patients, whereas arrhythmic death was 
most frequent in the randomized patients. 
Comparison of baseline characteristics of nonrandomized 
patients and patients randomized to placebo. Analysis of the 
baseline characteristics of the nonrandomized patients 
and patients randomized to placebo therapy confirms that 
nonrandomized patients have a greater extent of coronary 
heart disease and are a higher risk group. Several of the 
factors noted at baseline study in the nonrandomized pa-
tients (for example, older age, poorer left ventricular func-
tion, greater prevalence of prior myocardial infarction) are 
well recognized as risk factors for subsequent increased 
mortality (7-9). Reduced left ventricular function is also 
associated with a lower likelihood of suppression of ventric-
ular premature depolarizations (10) and reduced antiarrhyth-
mic drug efficacy assessed by electrophysiologic testing 
(11,12). 
Comparison of mortality during follow-up in nonrandom-
ized patients with that of a matched cohort of patients ran-
domized to placebo. One possibility that arises from the 
CAST results is that ability to suppress ventricular prema-
ture depolarizations with an antiarrhythmic drug is in itself a 
predictor of low mortality. This is based on the observation 
of the lower than expected mortality rate among the patients 
randomized to placebo who exhibited arrhythmia suppres-
sion. It is important to emphasize that in CAST, the patients 
randomized to placebo and the nonrandomized patients are 
not similar clinically and differed significantly in several 
important variables at baseline. We did attempt to examine 
this hypothesis more carefully by matching a cohort of the 
patients randomized to placebo in the main study with the 
318 nonrandomized patients and then comparing the fre-
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quency of end points in the nonrandomized patients with 
that in the matched cohort. Such a comparison does not 
strictly test this hypothesis because lack of suppression of 
ventricular premature depolarizations was only one of sev-
eral reasons why patients were not randomized. More pre-
cisely, it compares a "successful" attempt to suppress 
ventricular premature depolarizations (patients randomized 
to placebo) with an "unsuccessful" attempt (nonrandomized 
patients), although the definition of "unsuccessful" includes 
lack of suppression, adverse effects, disqualifying events 
and the personal decision to withdraw. 
In this analysis, we did not find any difference in the 
incidence of arrhythmic death or resuscitated cardiac arrest 
or that of total mortality or resuscitated cardiac arrest 
between nonrandomized patients and the matched cohort of 
patients randomized to placebo. Thus, although ease of 
arrhythmia suppression may identify those who will have a 
better outcome, this finding argues against the possibility 
that success after repeated attempts at suppression is an 
independent predictor of a low mortality rate and suggests a 
more conservative interpretation. It should be pointed out, 
however, that the small number of patients and events 
provides little power for the analysis in Figures 1 and 2. For 
example, if we assume (from Fig. 2) the 1 year event rate for 
total mortality or resuscitated cardiac arrest as 0.11 for 
nonrandomized patients and as 0.08 for the matched cohort, 
the "responder" effect is estimated as a 27% decrease in 
total mortality or resuscitated cardiac arrest. To detect this 
difference with an alpha of 0.025 and power of 0.85 (the 
CAST targets) would require approximately 2,857 patients in 
each group. Thus, it is not surprising that the present sample 
size of 318 is insufficient to ensure that the lack of observed 
difference is real. 
Clinical correlates of mortality in nonrandomized patients. 
The association of female gender with a poorer outcome in 
the nonrandomized patients is not readily explained. Female 
gender has intermittently been found to predict a poor 
outcome after myocardial infarction (13), coronary artery 
bypass surgery (14) and coronary angioplasty (15). Usually 
this gender difference disappears after adjustment for 
known risk factors (16). Differences that remain, such as 
that in the present analysis, may be due to factors that 
were not assessed. A difference between genders in the 
frequency of application of other helpful therapies (17,18) 
may be one such factor and, as an example, our data 
showed that nonrandomized women were given throm-
bolytic therapy less frequently than nonrandomized men. It 
is not surprising that a previous history of heart failure 
and reduced left ventricular ejection fraction increase the 
hazard ratio for total mortality or resuscitated cardiac arrest 
in the nonrandomized patients because these factors have 
been frequently implicated as risk factors for increased 
mortality (7,19). 
The fact that an adverse ECG event during open label 
drug titration had such a potent effect on the hazard ratio for 
arrhythmic death or resuscitated cardiac arrest may be 
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related to previous observations (20,21) on arrhythmias in 
patients after myocardial infarction. Patients who have ven-
tricular tachycardia, proarrhythmia or other ECG events 
such as bradycardia or widening of the QRS complex during 
antiarrhythmic drug titration seem to represent a very high 
risk group. The most appropriate treatment for such patients 
is unknown, but perhaps they should be considered for more 
aggressive evaluation and management, such as invasive 
electrophysiologic testing to test for arrhythmia inducibility 
followed by electrophysiologic testing to guide drug selec-
tion or selection of other modes of therapy (surgery or 
implantable devices). 
Reasons for withdrawal of nonrandomized patients. Pa-
tients who were withdrawn from drug treatment can be 
broadly categorized into two types: those for whom drug 
treatment could not be implemented because of adverse 
events or lack of drug efficacy, or both, and those who 
withdrew because of personal choice. Approximately 70% of 
the patients who were not randomized after open label drug 
titration in CAST fall into the first category and 30% into the 
second category. 
Comparison of results of open label titration on the first 
drug in nonrandomized patients and patients randomized to 
placebo. One of the main differences between the two 
groups of patients is that suppression of ventricular prema-
ture depolarizations was easily achieved with the first drug in 
patients randomized to placebo but not in nonrandomized 
patients. This is in part due to the criteria used to define the 
groups. However, lack of suppression was not the only 
reason why nonrandomized patients started treatment with a 
second drug or were withdrawn before starting double-blind 
therapy. In comparison with patients randomized to pla-
cebo, nonrandomized patients were more likely to have 
congestive heart failure or ventricular tachycardia during 
open label titration while taking the first drug. Heart failure 
(19) and ventricular tachycardia (20,21) in patients after 
myocardial infarction are well known to indicate a poor 
prognosis. The occurrence of these morbid events during 
open label titration indicates that these patients were a 
higher risk group than the patients randomized to placebo 
whose arrhythmia was suppressed. 
Implications for the CAST results. Although withdrawal 
of these patients before randomization reduced the number 
of end points in the double-blind portion of the study, it is 
interesting to speculate on how their inclusion in a different 
design may have altered the results. In a design in which 
randomization occurred at the point patients started open 
label titration, events in nonrandomized patients would have 
been included in the main study analysis. That design, 
however, may have obscured the drug effects found in CAST 
with flecainide and encainide. For example, one could 
hypothesize that nonrandomized patients would have been 
poorly compliant. If noncompliant patients with high event 
rates are equally distributed between treatment and placebo 
limbs of the study, the total event rate would be increased 
but the main study findings would be obscured because the 
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relative difference between treatment and placebo would 
have been reduced. We estimate that ~70% of the nonran-
domized patients could be predicted to contribute such a 
dilutional effect. 
Conclusions. Patients who survived open label titration in 
CAST but who were not randomized to double-blind therapy 
had a higher mortality rate than patients randomized to 
placebo; this may at least partly explain the low mortality in 
CAST placebo-randomized patients. However, nonrandom-
ized patients have more risk factors associated with de-
creased survival. The occurrence of proarrhythmia and 
other ECG events during open label titration portends a high 
risk of arrhythmic death. The data suggest that many of the 
patients who most need antiarrhythmic benefit are intolerant 
of the drugs. 
We are grateful for the expert assistance of Laurie Uhrich and Lynda Sharai 
in preparation of the manuscript. 
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